MelphalanTransplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationPeripheral Blood Stem Cell TransplantationMultiple MyelomaTransplantation, HomologousTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyBone Marrow TransplantationTreatment OutcomeRemission InductionStem CellsSalvage TherapyDisease-Free SurvivalBone MarrowEtoposideHodgkin DiseaseMyeloablative AgonistsCyclophosphamideLymphoma, Non-HodgkinRecurrenceCytarabineCarmustineGraft vs Host DiseaseBone Marrow PurgingHematopoietic Stem Cell MobilizationSurvival RateThiotepaVincristineBone Marrow CellsHematologic NeoplasmsHematopoietic Stem CellsWhole-Body IrradiationSurvival AnalysisAmyloidosisLymphoma, Mantle-CellRetrospective StudiesBusulfanAntineoplastic Agents, AlkylatingBoronic AcidsDexamethasoneGraft SurvivalPyrazinesDoxorubicinPrognosisAntigens, CD34Antibodies, Monoclonal, Murine-DerivedFollow-Up StudiesLymphoma, FollicularThalidomideAutograftsLymphoma, T-Cell, PeripheralLiver TransplantationTime FactorsMesenchymal Stem Cell TransplantationPrednisoneGranulocyte Colony-Stimulating FactorIfosfamideTransplantation ChimeraLeukapheresisLymphomaPodophyllotoxinAntineoplastic AgentsInduction ChemotherapyNeoplasm, ResidualTissue DonorsLeukemia, Myeloid, AcuteLymphoma, Large B-Cell, DiffuseMaintenance ChemotherapyCord Blood Stem Cell TransplantationCell TransplantationMyelodysplastic SyndromesKidney TransplantationLymphoma, B-CellEmbryonic Stem CellsEnteropathy-Associated T-Cell LymphomaLeukemia, Plasma CellMitoxantroneIdarubicinCell DifferentiationHematopoiesisInfusions, SpinalBone and BonesNeoplasms, Second PrimaryImmunosuppressive AgentsAdult Stem CellsHistocompatibility TestingProspective StudiesBlood Component RemovalAntibodies, MonoclonalLeukemia, MyeloidCarboplatinLeukemiaMesenchymal Stromal CellsFeasibility StudiesHistocompatibilityDrug Administration ScheduleFatal Outcome